0001567619-18-002677.txt : 20180914
0001567619-18-002677.hdr.sgml : 20180914
20180914181715
ACCESSION NUMBER: 0001567619-18-002677
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180912
FILED AS OF DATE: 20180914
DATE AS OF CHANGE: 20180914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bilenker Joshua H.
CENTRAL INDEX KEY: 0001612312
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36562
FILM NUMBER: 181072081
MAIL ADDRESS:
STREET 1: C/O LOXO ONCOLOGY, INC.
STREET 2: ONE LANDMARK SQUARE, SUITE 1122
CITY: STAMFORD
STATE: CT
ZIP: 06901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Loxo Oncology, Inc.
CENTRAL INDEX KEY: 0001581720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462996673
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
BUSINESS PHONE: 203-653-3880
MAIL ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
4
1
doc1.xml
FORM 4
X0306
4
2018-09-12
0
0001581720
Loxo Oncology, Inc.
LOXO
0001612312
Bilenker Joshua H.
C/O LOXO ONCOLOGY, INC.
ONE LANDMARK SQUARE, SUITE 1122
STAMFORD
CT
06901
1
1
0
0
President & CEO
Common Stock
2018-09-12
4
M
0
10000
1.184
A
145407
D
Common Stock
2018-09-12
4
S
0
700
164.1594
D
144707
D
Common Stock
2018-09-12
4
S
0
3700
165.1821
D
141007
D
Common Stock
2018-09-12
4
S
0
2400
166.4875
D
138607
D
Common Stock
2018-09-12
4
S
0
1800
167.3814
D
136807
D
Common Stock
2018-09-12
4
S
0
800
168.5125
D
136007
D
Common Stock
2018-09-12
4
S
0
200
169.8872
D
135807
D
Common Stock
2018-09-12
4
S
0
400
171.0750
D
135407
D
Common Stock
2018-09-13
4
M
0
7473
1.184
A
142880
D
Common Stock
2018-09-13
4
M
0
2527
3.648
A
145407
D
Common Stock
2018-09-13
4
S
0
5636
165.425
D
139771
D
Common Stock
2018-09-13
4
S
0
3402
166.523
D
136369
D
Common Stock
2018-09-13
4
S
0
962
167.3169
D
135407
D
Common Stock
30000
I
By Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018
Employee Stock Option (Right to Buy)
1.184
2018-09-12
4
M
0
10000
0
D
2023-11-14
Common Stock
10000
63932
D
Employee Stock Option (Right to Buy)
1.184
2018-09-13
4
M
0
7473
0
D
2023-11-14
Common Stock
7473
56459
D
Employee Stock Option (Right to Buy)
3.648
2018-09-13
4
M
0
2527
0
D
2024-06-18
Common Stock
2527
92985
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the aggregate of sales effected on the same day at different prices.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.75 to $164.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.75 to $165.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.02 to $167.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.04 to $168.0399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.06 to $169.0599 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.48 to $170.4799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.68 to $171.6799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.02 to $166.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.02 to $167.0199 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.18 to $168.1799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The options have fully vested and are immediately exercisable.
The stock option vests and becomes exercisable in 48 equal monthly installments beginning on the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
/s/Jennifer Burstein, by power of attorney
2018-09-14